Zoetis Inc. (ZTS) Receives Buy Rating from Stifel Nicolaus
Zoetis Inc. (NYSE:ZTS)‘s stock had its “buy” rating reaffirmed by Stifel Nicolaus in a report issued on Wednesday. They currently have a $58.00 price target on the stock. Stifel Nicolaus’ price target points to a potential upside of 12.80% from the stock’s previous close.
A number of other analysts have also commented on the company. Zacks Investment Research lowered Zoetis from a “buy” rating to a “hold” rating in a report on Thursday, October 6th. Bank of America Corp. assumed coverage on Zoetis in a report on Thursday, September 29th. They issued a “buy” rating and a $60.00 target price for the company. Jefferies Group reissued a “buy” rating and issued a $60.00 target price on shares of Zoetis in a report on Wednesday, September 14th. Argus lifted their target price on Zoetis from $54.00 to $58.00 and gave the stock a “below average” rating in a report on Friday, September 9th. Finally, Credit Suisse Group AG reissued a “focus list” rating and issued a $60.00 target price on shares of Zoetis in a report on Wednesday, September 7th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $55.27.
Zoetis (NYSE:ZTS) traded up 0.90% during mid-day trading on Wednesday, hitting $51.42. The company had a trading volume of 4,602,127 shares. The company has a market capitalization of $25.46 billion, a price-to-earnings ratio of 40.05 and a beta of 1.01. Zoetis has a 52 week low of $38.26 and a 52 week high of $53.14. The firm’s 50 day moving average is $51.24 and its 200 day moving average is $48.92.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/zoetis-inc-zts-receives-buy-rating-from-stifel-nicolaus.html
Zoetis (NYSE:ZTS) last posted its earnings results on Wednesday, August 3rd. The company reported $0.49 EPS for the quarter, topping the Zacks’ consensus estimate of $0.44 by $0.05. The business earned $1.20 billion during the quarter, compared to analyst estimates of $1.17 billion. Zoetis had a return on equity of 77.58% and a net margin of 13.15%. The company’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.43 EPS. On average, equities research analysts predict that Zoetis will post $1.91 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Thursday, November 3rd will be issued a $0.095 dividend. The ex-dividend date of this dividend is Tuesday, November 1st. This represents a $0.38 annualized dividend and a dividend yield of 0.74%. Zoetis’s dividend payout ratio (DPR) is 29.69%.
In other news, insider Heidi C. Chen sold 32,097 shares of Zoetis stock in a transaction dated Thursday, September 1st. The stock was sold at an average price of $50.98, for a total value of $1,636,305.06. Following the sale, the insider now directly owns 46,060 shares of the company’s stock, valued at $2,348,138.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Andrew Fenton sold 13,870 shares of Zoetis stock in a transaction dated Friday, September 2nd. The stock was sold at an average price of $51.25, for a total value of $710,837.50. Following the completion of the sale, the insider now directly owns 17,719 shares in the company, valued at $908,098.75. The disclosure for this sale can be found here. 0.05% of the stock is owned by insiders.
Several large investors have recently modified their holdings of the company. NEXT Financial Group Inc boosted its stake in shares of Zoetis by 9.5% in the second quarter. NEXT Financial Group Inc now owns 2,136 shares of the company’s stock valued at $101,000 after buying an additional 186 shares during the period. Kelly Lawrence W & Associates Inc. CA boosted its stake in shares of Zoetis by 113.4% in the second quarter. Kelly Lawrence W & Associates Inc. CA now owns 2,446 shares of the company’s stock valued at $116,000 after buying an additional 1,300 shares during the period. NN Investment Partners Holdings N.V. bought a new stake in shares of Zoetis during the first quarter valued at $118,000. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Zoetis by 22.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,566 shares of the company’s stock valued at $121,000 after buying an additional 476 shares during the last quarter. Finally, Glenmede Trust Co. NA boosted its stake in shares of Zoetis by 4.4% in the second quarter. Glenmede Trust Co. NA now owns 2,950 shares of the company’s stock valued at $139,000 after buying an additional 124 shares during the last quarter. 93.12% of the stock is currently owned by hedge funds and other institutional investors.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.